Block Drug
Executive Summary
Acquires Glaxo's (ITALICS)Ethamolin(END ITALICS) (ethanolamine oleate). The orphan product, approved in December 1988 for the treatment of bleeding esophageal varices and launched by Glaxo last June, will be marketed by Block's Reed & Carnrick ethical drug division. There are some 33,000 potential Ethamolin patients, Block noted.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.